Major depressive disorder (MDD) is a common mental health disorder that affects more than 264 million people globally, and it disproportionately affects women. GlobalData estimates the 12-month total prevalence of MDD for this year is twice as high in women, at 10.5%, as it is in men, at 5.5%, in the eight major markets (the […]

An international panel of mood disorder experts has published guidance on how to safely and effectively use ketamine and esketamine to treat adults with treatment-resistant depression (TRD). “Ketamine and esketamine are the first rapid-onset treatments for adults with TRD, and there was an international need for best-practice guidance on the deft and safe implementation of

Children with elevated interleukin-6 (IL-6) may be at increased risk for psychosis and depression during adulthood. These findings, from a birth cohort study, were published in Schizophrenia Research. Pregnant women (N=14,541) were recruited for the Avon Longitudinal Study of Parents and Children (ALPAC) study in southwest England between 1991 and 1992. IL-6 and C-reactive protein

Late last year, if you happened to visit San Francisco’s Golden Gate Park, you might have stumbled upon artists on six-foot-tall stilts, sharing reminders of social distancing and mask wearing. Or you might have spotted a musician strumming guitar melodies, accompanied by a woman in a butterfly costume — a “social distance butterfly” out to

Bob Azelby, CEO of Eliem Therapeutics, pictured above. (Doug Pensinger/Getty Images) Eliem Therapeutics emerged from stealth mode with $80 million in financing that will be used to develop therapeutics aimed at treating neuronal excitability disorders such as chronic pain, depression, epilepsy and anxiety. The disorders Eliem is targeting have a wide patient population across the globe.

Depression, which has been recognized as a prevalent condition, has become more pervasive due to the pandemic. A Gartner, Inc. survey of more than 5,000 employees conducted in the fourth quarter of 2020 found that more than one-quarter of the workforce (29%) described itself as depressed as a result of the  COVID-19 pandemic. Employers are

Depression is the fourth most common causes of disease burden worldwide, and according to the World Health Organization, it is expected to rank first in the 2030s​. The majority of studies investigating associations of dietary patterns with depression have focused on adherence to the Mediterranean diet and recent meta-analyses concluded that this diet was generally associated

WEDNESDAY, March 24, 2021 (HealthDay News) — The COVID-19 pandemic has caused large disruptions to physical activity, sleep, time use, and mental health among young adults, according to a study published March 2 in the Proceedings of the National Academy of Sciences. Osea Giuntella, Ph.D., from the University of Pittsburgh, and colleagues linked biometric and

Dive Brief: The need for employers to focus mental health amid the pandemic “skyrocketed” amid the pandemic as many employees reported having depression, a Gartner report released March 15 found. In response, most employers took “emergency measures” to support their staff, according to the research and advisory company.  In the fourth quarter of 2020, Gartner

What does this paper contribute to the wider global clinical community? Among those who worked in COVID‐19 units, those in the suspected patients unit showed significantly higher anxiety and depression than those working in the confirmed patients unit, suggesting that insufficient support and uncertainty about infectious status of patients further promoted anxiety and affected depression.